Pfizer News and Research

RSS

Novel platform identifies genes that control biologic processes

Inflammatory neurological diseases, such as multiple sclerosis (MS), can arise when cell-to-cell communication between cells in the central nervous system (CNS) goes awry. But exactly how this cellular crosstalk leads to the molecular changes that drive disease remain unknown.

13 Mar 2023

Regulatory T cells produced in the gut play a role in repairing injured muscles

The human immune system is incredibly versatile. Among its most skilled multitaskers are T cells, known for their role in everything from fighting infection to reining in inflammation to killing nascent tumors.

3 Mar 2023

Study uncovers differences in how AstraZeneca and Pfizer COVID-19 vaccines affect the immune system

A new Australian study led by SAHMRI and Flinders University has uncovered fundamental differences in how the AstraZeneca and Pfizer COVID-19 vaccines impact the immune system.

23 Feb 2023

The influence of genes and small molecules on personal disease risk

Each individual has a unique chemical fingerprint. Small molecules in the blood, like fats or sugars, have a significant impact on how the human body responds to stress, which diseases people are predisposed to, and how serious an illness will be.

23 Nov 2022

Applying “programmable molecular scissors” to combat COVID-19 infection

As an approach that could be used to create a new class of antiviral drugs, synthetic biology was used by Cambridge scientists to artificially create enzymes programmed to attack the genetic code of SARS-CoV-2 and eliminate the virus.

17 Nov 2022

NIH funds research on mRNA vaccines to stop cancer development

The National Cancer Institute at the National Institutes of Health has awarded a multidisciplinary team of Weill Cornell Medicine researchers a five-year $5.7 million grant to support a center dedicated to creating messenger RNA (mRNA) vaccines to prevent the development of cancer in at-risk groups.

15 Nov 2022

New technique could help fine-tune the production of useful proteins

Using an approach based on CRISPR proteins, MIT researchers have developed a new way to precisely control the amount of a particular protein that is produced in mammalian cells.

2 Nov 2022

New open-source tool automates RNA analysis, likely to encourage research and drug development

Scripps Research scientists have introduced a new software tool for examining RNA (ribonucleic acid) molecules, which play a variety of important roles in living things.

10 May 2022

Researchers analyze the potential role of mRNA in drug development and novel therapies

In latest years, messenger RNA—the DNA’s close relative in the complex process of turning a string of genetic blueprints into a properly functioning organism—has gotten a lot of attention in the scientific and medical community.

29 Apr 2022

Experimental "gene silencing" therapy reduces a important driver of heart disease risk by up to 98%

Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental "gene silencing" therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.

4 Apr 2022

Novel method to sneak large drug-carrying biological molecules into cells

Scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed a novel method of delivering drugs into human cells using large biological molecules, by first encasing them in a protein-based microdroplet.

From Nanyang Technological University Singapore (NTU Singapore) 17 Mar 2022

Study shows how two distinct groups of Tregs play different roles at different times

Every kind of T cell has a job to do. A healthy immune system makes sure no T cell oversteps.

22 Feb 2022

Discovery of chiral evasion could lead to more resilient inhibitors, better drug designs

Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterial infection that has become resistant to most of the antibiotics used to treat regular staph infections.

18 Feb 2022

New vaccine providing protection against future animal-to-human viral diseases may be possible

A future vaccine providing protection against a wide range of coronaviruses that jump from their original animal hosts to humans -; including SARS-CoV-2, the cause of COVID-19 -; may be possible, say Johns Hopkins Medicine researchers, based on findings from their recent study.

17 Feb 2022

Single-cell sequencing technique helps to examine early SARS-CoV-2 infection

In the early days of SARS-CoV-2 infection in the lungs, what happens at the single-cell level?

14 Feb 2022

COVID-19 vaccines prompt the body to make long-lasting T cells against different variants

Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2.

25 Jan 2022

Omicron variant hampers the effectiveness of vaccines and monoclonal antibodies, study shows

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries.

From Institut Pasteur 10 Jan 2022

Researchers develop new CAR T cells that act as a "micropharmacy"

Immunotherapies called chimeric antigen receptor (CAR) T cells use genetically engineered versions of a patient's own immune cells to fight cancer. These treatments have energized cancer care, especially for people with certain types of blood cancers.

3 Jan 2022

Breakthrough infections enhance immune response to COVID-19 variants

Breakthrough infections greatly enhance immune response to variants of the virus that causes COVID-19, according to a newly published study from Oregon Health & Science University.

17 Dec 2021

Single-cell spatial analysis may provide information about neoadjuvant therapy for triple-negative breast cancer

A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME) was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab (Tecentriq) to chemotherapy as neoadjuvant treatment for patients with early high-risk and locally advanced triple negative breast cancer (TNBC), according to results presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.

8 Dec 2021